<DOC>
	<DOCNO>NCT01910441</DOCNO>
	<brief_summary>Compare effect Vildagliptin plus Metformin versus Glimepiride plus Metformin glucose variability T2DM patient .</brief_summary>
	<brief_title>Comparison Vildagliptin vs. Glimepiride Glucose Variability Metformin Uncontrolled Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patients give write informed consent participate study . 2 . Type 2 Diabetes Mellitus patient either Male female 18 75 year age ( inclusive ) . 3 . Patients uncontrolled metformin monotherapy least past 4 week ( 10001500 mg daily HbA1c &gt; 7.5 9 % ) . 4 . Patients HbA1C level within range &gt; 7.5 % 9 % . ( If past value available within last 12 week , would consider acceptable provide obtain least 4 week metformin therapy 10001500 mg daily ) . 1 . Age &gt; 75 year ; BMI &lt; 22 &gt; 40 kg/m2 2 . Patients Insulin therapy time study entry . 3 . Type 1 Diabetes Mellitus patient . 4 . Patients severe renal ( creatinine clearance &lt; 50 ml/min ) hepatic impairment ( include pretreatment ALT AST &gt; 3 x ULN ) . Creatinine clearance estimate serum creatinine use CockcroftGault formula ( Cockcroft Gault , 1976 ) 5 . Patients contraindication mention Summary Product Characteristics ( SPCs ) vildagliptin , metformin , glimepiride , vildagliptin plus metformin glimiperide plus metformin . Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Type 2 Diabetes Mellitus , Glycemic variability</keyword>
</DOC>